Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MLN 944

Known as: MLN-944, MLN944 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
MLN 944 is a bisintercalating DNA-binding antitumor agent known to be a template inhibitor of transcription. Previous (1) H NMR… Expand
Is this relevant?
2005
2005
XR5944 (MLN944), a novel bis-phenazine, has demonstrated potent cytotoxic activity against a variety of murine and human tumour… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2005
2005
MLN944 is a novel compound currently being codeveloped by Millennium Pharmaceuticals and Xenova Ltd. as a cancer therapeutic and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical trials that has demonstrated potent cytotoxic activity… Expand
Is this relevant?
2004
2004
The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of… Expand
  • figure 1
  • table I
  • figure 2
  • figure 3
  • table II
Is this relevant?
2004
2004
MLN944 (XR5944) is a novel bis-phenazine that has demonstrated exceptional efficacy against a number of murine and human tumor… Expand
Is this relevant?
2004
2004
XR5944 (MLN944) is a novel DNA targeting agent with potent antitumor activity, both in vitro and in vivo, against several murine… Expand
Is this relevant?
2004
2004
2100 Background: XR5994 (MLN944) is a novel DNA/RNA targeting agent with a mechanism of action distinct from that of currently… Expand
Is this relevant?